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■ RESEARCH LETTER ■
Dermatomyositis is a rare systemic inflammatory my-
opathy with characteristic cutaneous manifestations
consisting of heliotrope erythema, Gottron’s papules,
poikiloderma, and periungual telangiectasia [1]. Diag-
nosis is based on characteristic skin lesions and ad-
ditional laboratory examination results. Laboratory
confirmation of dermatomyositis includes increased lev-
els of serum muscle enzymes (creatine phosphokinase,
aldolase, and lactate dehydrogenase) and electromyo-
graphic changes. Although the underlying pathogene-
sis remains elusive, the association of this disease with
malignancies is well known. Documented data from
Scandinavia shows increased rates of malignant diseases
in patients with dermatomyositis, compared with the
general population [2,3]. We report here a case of epi-
thelial ovarian cancer with an initial presentation of
dermatomyositis. The manifestations of dermatomyosi-
tis regressed in synchrony with effective treatment of
the tumor with surgery and systemic chemotherapy.
A 60-year-old, multipara, menopausal woman, with
no remarkable medical history, presented to our derma-
tology clinic with a complaint of intermittent facial
erythema for about 2 months. It was mainly distrib-
uted on the bilateral cheeks and forehead. Progressive
symmetrical muscle weakness, which led to difficulty
in cooking and climbing upstairs, was also reported,
together with progressive abdominal distension and in-
creased abdominal circumference noted 10 days prior to
admission. On physical examination, cutaneous lesions
consisting of generalized confluent macules and viola-
ceous erythema were found on the face, trunk, and all
four limbs (Figure). Periorbital heliotrope flushing associ-
ated with some degree of edema, violaceous papules
over the knuckles (Gottron’s sign), and periungual ery-
thema with telangiectasia were also noted. Skin biopsy
was suggested but was refused by the patient. Abdominal
distension was present with no palpable abdominal
mass. On neurologic examination, the muscle power of
the bilateral arm, forearm and thigh muscles had de-
creased to grade 4, while that of the unaffected muscles
remained at grade 5. The results of laboratory examina-
tion revealed elevated levels of creatinine phosphokinase
(102 IU/L). The autoimmune disease profile was nor-
mal, except for antinuclear antibodies, which were pres-
ent at 1:160 + , in a speckle pattern. Myopathy was
implied by electromyography results, which showed nu-
merous small-amplitude and short-duration polyphasic
waves with early recruitment in the right biceps. The skin
lesions and muscle weakness were only partially improved
by steroid treatment.
Chest X-ray, mammography, and ear, nose and throat
examinations were performed to screen for possible
underlying malignancies, but the results were normal.
Panendoscopy failed to disclose any lesions suggestive
of malignancy. In light of the recent onset abdominal dis-
tension, a gynecologic consultation was requested. Pelvic
examination disclosed an atrophic-sized uterus and
impalpable bilateral adnexa. Transvaginal sonography
showed bilateral adnexal tumors with profound as-
cites. Ascites cytology revealed adenocarcinoma. Tumor
markers were determined as: CA-125, 1,322.9 IU/mL;
and CA-153, 103.4 IU/mL. A chest-abdomen-pelvis
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Figure. Cutaneous lesions with generalized confluent macules
and violaceous erythema on the patient’s back.
computerized tomographic scan confirmed bilateral
ovarian solid tumors measuring 4.2 × 3.4 cm and
3.1 × 2.3 cm. Dirty infiltrations with increased soft tis-
sue density on the mesentery and massive ascites were
also noted. The patient was transferred to the gynecolo-
gic ward owing to suggested ovarian malignancy.
The patient underwent uncomplicated exploratory
laparotomy in which bilateral ovarian tumors with papill-
ary growth and diffuse peritoneal seeding were observed.
A total abdominal hysterectomy, bilateral salpingo-
oophorectomy, infracolic omentectomy, and bilateral
pelvic lymph node dissection were performed. Suboptimal
debulking surgery was achieved, and the residual tumor
measuring > 2 cm was mainly located in the perirectal
area and over the visceral peritoneal surfaces. Results
of the final histopathologic examination confirmed a
high-grade serous adenocarcinoma of the ovaries with
omental metastasis, classified as International Federation
of Gynecology and Obstetrics stage IIIC ovarian can-
cer. She completed five courses of adjuvant chemother-
apy with paclitaxel (175 mg/m2) and carboplatin (area
under the curve, 6 mg/mL · min). The sixth course of
chemotherapy was not delivered because of impaired
liver function. The skin lesions and muscle weakness
resolved completely with the normalization of CA-125
levels. However, CA-125 rose again 5 months after the
initial chemotherapy, and the dermatomyositis reap-
peared. Abdominopelvic magnetic resonance imaging
revealed multiple enlarged lymph nodes in the bilateral
iliac chains. Salvage chemotherapy with liposomal
doxorubicin (40mg/m2) and carboplatin (area under the
curve, 6 mg/mL · min) were prescribed for platinum-
resistant recurrent ovarian cancer. The symptoms of
dermatomyositis resolved dramatically after the third
course of salvage chemotherapy, and the patient was
still receiving treatment at the time of writing this report.
Dermatomyositis is a rare disease with an incidence
of 0.7–1.0/100,000 in the general population [4]. Its
clinical significance lies in the fact that it is probably 
a paraneoplastic event in some patients. A large retro-
spective study showed that up to 15% of dermatomyosi-
tis patients had underlying malignancies [3]. Ovarian,
lung and colorectal cancers were frequently diagnosed
both before and after the diagnosis of dermatomyositis,
suggesting that these could be candidate cancers asso-
ciated with the disease.
In a review of the literature, Cherin et al [5] reported
six cases of dermatomyositis with ovarian cancer in a
series of 56 dermatomyositis patients (including 45
women). The incidence of ovarian cancer in the female
patients with dermatomyositis (13.3%) was much
higher than that observed in the general female popu-
lation (1%). Moreover, in women older than 40 years
with dermatomyositis, there was a high incidence of
ovarian cancer among the associated internal malig-
nancies (6/28) [5]. Nevertheless, the early detection of
ovarian cancer among these patients is not substan-
tially higher. In a case series reported by Davis and
Ahmed [6], six dermatomyositis patients had abdomi-
nal symptoms at presentation. All had undergone pre-
vious screening for ovarian cancer, but ovarian disease
was not found in any of them. In the case series
reported by Mordel et al [7], the diagnosis of derma-
tomyositis preceded that of ovarian cancer in most cases,
with a mean interval of 10.9 months. Delayed diagnosis
could be due to the insidious onset and slow progression
of dermatomyositis and the limitations of imaging stud-
ies. Ninety-four percent of patients were diagnosed as
stage III or IV, rendering their prognosis extremely poor
[7]. Death from ovarian malignancies associated with
dermatomyositis was 100%, and the mean survival time
from diagnosis was 11 months (range, 0–28 months) in
the series described by Davis and Ahmed [6]. Gynecolo-
gists should, therefore, be aware of the significance of
the association between these two conditions.
Some previous studies have described cases of der-
matomyositis presented after an established diagnosis
of ovarian cancer [8]. However, as in the present case,
the diagnosis of ovarian cancer may occur shortly after
the diagnosis of dermatomyositis [9]. The risk of can-
cer was highest during the first year following the diag-
nosis of dermatomyositis, and dropped substantially
thereafter. However, the risk of ovarian cancer did not
return to the expected population value for up to 5 years
after diagnosis of dermatomyositis [1]. A thorough phy-
sical examination, pelvic ultrasound and serum CA-125
assay should, therefore, be performed at the time of pre-
sentation and patients should be closely followed for
several years.
In our patient, the manifestations of dermatomyosi-
tis regressed in synchrony with effective treatment of the
tumor. Although dermatomyositis may follow a para-
neoplastic course or may follow its own course, inde-
pendent of tumor therapy [10], clinicians should be
vigilant for the recurrence of muscle weakness and cuta-
neous manifestations that are associated with relapse
of the malignant disease in most cases.
In summary, the link between dermatomyositis and
ovarian cancer should be clearly emphasized. As ovarian
cancer is the most lethal gynecologic cancer, clinicians
should perform timely screening in patients with der-
matomyositis to detect those with occult cancer, espe-
cially in female patients older than 40 years. Even if
mortality cannot be prevented in these ovarian cancer
patients, disability from myositis can be alleviated when
the cancers are well managed.
Taiwan J Obstet Gynecol • June 2009 • Vol 48 • No 2 179
Dermatomyositis and Ovarian Cancer
Taiwan J Obstet Gynecol • June 2009 • Vol 48 • No 2180
L.W. Chao, L.H. Wei
References
1. Callen JP. Dermatomyositis. Lancet 2000;355:53–7.
2. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of spe-
cific  cancer types in dermatomyositis and polymyositis: 
a population-based study. Lancet 2001;357:96–100.
3. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of
cancer in patients with dermatomyositis or polymyositis: a
population-based study. N Engl J Med 1992;326:363–7.
4. Menczer J, Ben-Baruch B. Malignant Tumors of the Female
Genitalia. Tel Aviv: Modan Publishing House, 1988.
5. Cherin P, Piette JC, Herson S, Bletry O, Wechsler B, Frances C,
Godeau P. Dermatomyositis and ovarian cancer: a report of
7 cases and literature review. J Rheumatol 1993;20:1897–9.
6. Davis M, Ahmed I. Ovarian malignancy in patients with
dermatomyositis and polymyositis: a retrospective analysis
of fourteen cases. J Am Acad Dermatol 1997;37:730–3.
7. Mordel N, Margalioth EJ, Harats N, Ben-Baruch N,
Schenker JG. Concurrence of ovarian cancer and dermato-
myositis: a report of two cases and literature review. J Reprod
Med 1988;33:649–55.
8. Ben-Zvi N, Shani A, Ben-Baruch G, et al. Dermatomyositis
following the diagnosis of ovarian cancer. Int J Gynecol Cancer
2005;15:1124–6.
9. Nakanishi K, Cualing H, Husseinzadeh N. Dermatomyositis
as a presenting symptom of ovarian cancer. Obstet Gynecol
1999;94:836–8.
10. Callen JP. The value of malignancy evaluation in patients
with dermatomyositis. J Am Acad Dermatol 1982;6:253–9.
